Overview

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Status:
Not yet recruiting

Trial end date:
2026-05-15

Target enrollment:

Participant gender:

Summary

A clinical study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of patients with newly diagnosed advanced ovarian cancer who are planned to receive neoadjuvant treatment followed by interval debulking surgery (IDS) and adjuvant treatment.

Phase:

Phase 2

Details

Lead Sponsor:

CanariaBio Inc.

Collaborator:

Raptim Research Pvt. Ltd

Treatments:

Carboplatin
Oregovomab
Paclitaxel